Manufacturer record
Enrico Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Enrico Pharmaceuticals (Himachal Pradesh) was declared Not of Standard Quality in February 2019. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: EN1804140T, Letrozole Tablets USP 2.5 mg (BREXOL-2.5 TABLETS) (exp Mar 2020). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Dissolution (Letrozole). Listed in the February 2019 alert.
Records by type
1 record linked to Enrico Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Letrozole Tablets USP 2.5 mg (BREXOL-2.5 TABLETS) | Batch EN1804140TMfg Apr 2018 · Exp Mar 2020 | Dissolution (Letrozole).Dissolution | RDTL ChandigarhCDSCO lab | Feb 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.